Display options
Cite
Rey F, Ottolenghi S, Giallongo T, et al. Mitochondrial Metabolism as Target of the Neuroprotective Role of Erythropoietin in Parkinson's Disease. Antioxidants (Basel). 2021;10(1)doi: 10.3390/antiox10010121.
Rey, F., Ottolenghi, S., Giallongo, T., Balsari, A., Martinelli, C., Rey, R., Allevi, R., Giulio, A. M. D., Zuccotti, G. V., Mazzucchelli, S., Foresti, R., Samaja, M., & Carelli, S. (2021). Mitochondrial Metabolism as Target of the Neuroprotective Role of Erythropoietin in Parkinson's Disease. Antioxidants (Basel, Switzerland), 10(1), . https://doi.org/10.3390/antiox10010121
Rey, Federica, et al. "Mitochondrial Metabolism as Target of the Neuroprotective Role of Erythropoietin in Parkinson's Disease." Antioxidants (Basel, Switzerland) vol. 10,1 (2021). doi: https://doi.org/10.3390/antiox10010121
Rey F, Ottolenghi S, Giallongo T, Balsari A, Martinelli C, Rey R, Allevi R, Giulio AMD, Zuccotti GV, Mazzucchelli S, Foresti R, Samaja M, Carelli S. Mitochondrial Metabolism as Target of the Neuroprotective Role of Erythropoietin in Parkinson's Disease. Antioxidants (Basel). 2021 Jan 15;10(1). doi: 10.3390/antiox10010121. PMID: 33467745; PMCID: PMC7830512.
Copy Download .nbib Format: NLM
Share it on

Antioxidants (Basel). 2021 Jan 15;10(1). doi: 10.3390/antiox10010121.

Mitochondrial Metabolism as Target of the Neuroprotective Role of Erythropoietin in Parkinson's Disease.

Antioxidants (Basel, Switzerland)

Federica Rey, Sara Ottolenghi, Toniella Giallongo, Alice Balsari, Carla Martinelli, Robert Rey, Raffaele Allevi, Anna Maria Di Giulio, Gian Vincenzo Zuccotti, Serena Mazzucchelli, Roberta Foresti, Michele Samaja, Stephana Carelli

Affiliations

  1. Laboratory of Pharmacology, Department of Health Sciences, University of Milan, Via Antonio di Rudinì 8, 20142 Milano, Italy.
  2. Pediatric Clinical Research Center Fondazione "Romeo ed Enrica Invernizzi", Department of Biomedical and Clinical Sciences, University of Milan, 20157 Milan, Italy.
  3. Laboratory of Biochemistry, Department of Health Sciences, University of Milan, Via Antonio di Rudinì 8, 20142 Milano, Italy.
  4. Laboratory of Pathological Anatomy, Department of Health Sciences, University of Milan, Via Antonio di Rudinì 8, 20142 Milano, Italy.
  5. Department of Pediatrics, Children's Hospital "V. Buzzi", 20154 Milan, Italy.
  6. University Paris Est Creteil, INSERM, IMRB, F-94010 Créteil, France.

PMID: 33467745 PMCID: PMC7830512 DOI: 10.3390/antiox10010121

Abstract

Existing therapies for Parkinson's disease (PD) are only symptomatic. As erythropoietin (EPO) is emerging for its benefits in neurodegenerative diseases, here, we test the protective effect driven by EPO in in vitro (SH-SY5Y cells challenged by MPP

Keywords: Parkinson’s disease; erythropoietin (EPO); mitochondrial metabolism; neuroprotection; redox imbalance; tyrosine hydroxylase (TH)

References

  1. Neuron. 2011 Jun 23;70(6):1033-53 - PubMed
  2. Nat Rev Neurosci. 2005 Jun;6(6):484-94 - PubMed
  3. Proc Natl Acad Sci U S A. 2009 Feb 3;106(5):1602-7 - PubMed
  4. Cold Spring Harb Perspect Med. 2013 Mar 01;3(3):a011619 - PubMed
  5. Biochem J. 2015 Apr 15;467(2):303-10 - PubMed
  6. Neuropharmacology. 2017 Jun;119:76-90 - PubMed
  7. J Mol Neurosci. 2014 May;53(1):117-24 - PubMed
  8. J Med Virol. 2020 Jul;92(7):915-918 - PubMed
  9. N Engl J Med. 2005 Sep 8;353(10):1021-7 - PubMed
  10. Behav Brain Res. 2015 Nov 1;294:198-207 - PubMed
  11. Clin Sci (Lond). 2014 Sep;127(6):367-73 - PubMed
  12. Exp Neurol. 2017 Dec;298(Pt B):210-224 - PubMed
  13. Int J Mol Sci. 2020 May 04;21(9): - PubMed
  14. Mol Neurodegener. 2017 Jan 24;12(1):10 - PubMed
  15. J Pathol. 2017 Jan;241(2):251-263 - PubMed
  16. Mol Neurobiol. 2016 Aug;53(6):3812-3821 - PubMed
  17. Int J Mol Sci. 2012;13(9):11102-29 - PubMed
  18. Br J Pharmacol. 2013 Aug;169(7):1461-76 - PubMed
  19. Neurosci Lett. 2001 Feb 2;298(2):139-41 - PubMed
  20. Nat Commun. 2020 Mar 9;11(1):1313 - PubMed
  21. Biochem Biophys Res Commun. 2014 Mar 28;446(1):79-84 - PubMed
  22. Pathobiology. 2011;78(1):41-53 - PubMed
  23. Int J Mol Med. 2014 Aug;34(2):440-50 - PubMed
  24. J Neuroinflammation. 2017 Mar 21;14(1):60 - PubMed
  25. J Neuroinflammation. 2018 Nov 30;15(1):333 - PubMed
  26. Br J Pharmacol. 2007 Apr;150(8):963-76 - PubMed
  27. Cell Mol Neurobiol. 2006 Jul-Aug;26(4-6):659-78 - PubMed
  28. J Neurol Sci. 2014 Feb 15;337(1-2):47-54 - PubMed
  29. Neurol Sci. 2016 Feb;37(2):243-52 - PubMed
  30. Free Radic Biol Med. 2017 Mar;104:311-323 - PubMed
  31. Lancet Neurol. 2019 Dec;18(12):1072-1074 - PubMed
  32. Stroke. 2013 Mar;44(3):753-8 - PubMed
  33. Anat Rec (Hoboken). 2013 Mar;296(3):378-81 - PubMed
  34. J Exp Biol. 2004 Aug;207(Pt 18):3233-42 - PubMed
  35. J Clin Invest. 2019 Oct 1;129(10):4539-4549 - PubMed
  36. Neuroreport. 2019 Aug 7;30(11):783-789 - PubMed
  37. Respir Physiol Neurobiol. 2020 Aug;279:103476 - PubMed
  38. Rom J Physiol. 2000 Jan-Dec;37(1-4):3-14 - PubMed
  39. Neurotoxicology. 2005 Oct;26(5):923-8 - PubMed
  40. Proc Natl Acad Sci U S A. 2004 Oct 12;101(41):14907-12 - PubMed
  41. J Comp Neurol. 2006 Jan 20;494(3):495-514 - PubMed
  42. Sci Rep. 2016 May 05;6:25344 - PubMed
  43. Trends Endocrinol Metab. 1999 Dec;10(1):18-23 - PubMed
  44. Proc Natl Acad Sci U S A. 1995 Apr 25;92(9):3717-20 - PubMed
  45. Cell Signal. 2020 May;69:109554 - PubMed
  46. J Neurosci Methods. 2003 Mar 15;123(2):189-200 - PubMed
  47. Prog Neurobiol. 2013 Jul-Aug;106-107:17-32 - PubMed
  48. MEDICC Rev. 2012 Jan;14(1):11-7 - PubMed
  49. Ultrastruct Pathol. 2003 Nov-Dec;27(6):409-16 - PubMed
  50. Neurotoxicology. 2009 Jan;30(1):127-35 - PubMed
  51. Cell Death Dis. 2012 May 24;3:e312 - PubMed
  52. PLoS One. 2012;7(9):e44610 - PubMed
  53. Redox Biol. 2018 Apr;14:285-294 - PubMed
  54. Eur J Gastroenterol Hepatol. 2001 Jul;13(7):791-801 - PubMed
  55. J Neurosci Res. 2018 Jan;96(1):103-116 - PubMed
  56. Mol Med. 2020 Jun 16;26(1):58 - PubMed
  57. J Neurochem. 2016 Nov;139(4):596-609 - PubMed
  58. BMC Med Genomics. 2012 Jun 29;5:29 - PubMed
  59. Proc Natl Acad Sci U S A. 2005 Nov 8;102(45):16379-84 - PubMed
  60. Hypoxia (Auckl). 2016 Aug 16;4:121-133 - PubMed
  61. Mol Cell Neurosci. 2020 Dec;109:103554 - PubMed
  62. Front Immunol. 2014 Oct 22;5:523 - PubMed
  63. Neuropharmacology. 2009 May-Jun;56(6-7):1027-34 - PubMed
  64. Free Radic Res. 2017 Apr;51(4):413-427 - PubMed
  65. Proc Natl Acad Sci U S A. 2003 May 27;100(11):6741-6 - PubMed
  66. Redox Biol. 2017 Apr;11:12-20 - PubMed
  67. Front Horm Res. 2016;47:115-27 - PubMed
  68. Glia. 2000 May;30(3):271-8 - PubMed
  69. Brain Res. 2010 Jun 14;1337:85-94 - PubMed
  70. Int J Neurosci. 2012 May;122(5):255-62 - PubMed
  71. Front Neuroanat. 2015 Jul 08;9:91 - PubMed
  72. Neuropeptides. 2015 Feb;49:1-5 - PubMed
  73. Neurobiol Dis. 2011 Jul;43(1):86-98 - PubMed
  74. ASN Neuro. 2019 Jan-Dec;11:1759091419871420 - PubMed
  75. Mol Med. 2012 May 09;18:486-96 - PubMed
  76. Brain. 2010 Jan;133(Pt 1):189-204 - PubMed
  77. J Neural Transm (Vienna). 2017 Aug;124(8):901-905 - PubMed
  78. ASN Neuro. 2016 Oct 27;8(5): - PubMed
  79. Redox Biol. 2019 Jun;24:101187 - PubMed
  80. Brain Res. 2010 Jan 8;1306:176-83 - PubMed
  81. J Physiol. 2007 Aug 15;583(Pt 1):329-36 - PubMed
  82. Neurosci Bull. 2007 May;23(3):156-64 - PubMed

Publication Types